The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo

Roflumilast is a new phosphodiesterase 4 (PDE4) inhibitor developed by Byk Gulden Pharmaceuticals for the treatment of chronic obstructive pulmonary disease and asthma. A placebo-controlled, randomized, double-blind, two-period crossover study was performed to investigate the safety and efficacy of roflumilast in 16 patients with exercise-induced asthma. The patients received placebo or roflumilast (500 microg/day) for 28 days, each according to the randomly determined treatment sequences roflumilast/placebo and placebo/roflumilast. In both study periods, exercise challenge was performed 1 hour after dosing on days 1, 14, and 28. FEV1 was measured before exercise challenge, immediately after the end of exercise challenge, and then at 1, 3, 5, 7, 9, and 12 minutes after the end of challenge. Blood samples for the determination of lipopolysaccharide (LPS)-stimulated tumor necrosis factor alpha (TNF-alpha) in whole blood ex vivo as a surrogate marker for the inhibition of inflammatory cell activation were taken predose on days 1 and 28. Serial safety measurements were performed during both study periods. Analysis of variance for the crossover design showed a significant superiority of roflumilast over placebo on day 28. The mean percentage fall of FEV1 after exercise was reduced by 41% as compared to placebo (p = 0.021). An improvement of lung function during roflumilast treatment was also observed on days 1 and 14. The median TNF-alpha level decreased by 21% (p = 0.009) during roflumilast treatment but remained essentially constant under placebo. It is concluded that roflumilast is effective in the treatment of exercise-induced asthma. This result was accompanied by a significant reduction of TNF-alpha levels ex vivo. Treatment with roflumilast was safe and well tolerated.
CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. M. Bohmer, N. Nassr, M. Wenger, A. Hunnemeyer, G. Lahu, S. Templin, C. H. Gleiter, and R. Hermann The Targeted Oral, Once-Daily Phosphodiesterase 4 Inhibitor Roflumilast and the Leukotriene Receptor Antagonist Montelukast Do Not Exhibit Significant Pharmacokinetic Interactions J. Clin. Pharmacol., April 1, 2009; 49(4): 389 - 397. [Abstract] [Full Text] [PDF]

				Y. P. de Visser, F. J. Walther, E. H. Laghmani, S. van Wijngaarden, K. Nieuwland, and G. T. M. Wagenaar Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury Eur. Respir. J., March 1, 2008; 31(3): 633 - 644. [Abstract] [Full Text] [PDF]

				H. Mori, T. Nose, K. Ishitani, S. Kasagi, S. Souma, T. Akiyoshi, Y. Kodama, T. Mori, M. Kondo, S. Sasaki, et al. Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 strain Am J Physiol Lung Cell Mol Physiol, February 1, 2008; 294(2): L196 - L204. [Abstract] [Full Text] [PDF]

				J. A. Meyers, J. Taverna, J. Chaves, A. Makkinje, and A. Lerner Phosphodiesterase 4 Inhibitors Augment Levels of Glucocorticoid Receptor in B Cell Chronic Lymphocytic Leukemia but Not in Normal Circulating Hematopoietic Cells Clin. Cancer Res., August 15, 2007; 13(16): 4920 - 4927. [Abstract] [Full Text] [PDF]

				T. D. Bethke, G. M. Bohmer, R. Hermann, B. Hauns, R. Fux, K. Morike, M. David, D. Knoerzer, W. Wurst, and C. H. Gleiter Dose-Proportional Intraindividual Single- and Repeated-Dose Pharmacokinetics of Roflumilast, an Oral, Once-Daily Phosphodiesterase 4 Inhibitor J. Clin. Pharmacol., January 1, 2007; 47(1): 26 - 36. [Abstract] [Full Text] [PDF]

				A. M. Jeffrey, M. J. Iatropoulos, and G. M. Williams Nasal Cytotoxic and Carcinogenic Activities of Systemically Distributed Organic Chemicals Toxicol Pathol, December 1, 2006; 34(7): 827 - 852. [Abstract] [Full Text] [PDF]

				S. B Karish and J. M Gagnon The Potential Role of Roflumilast: The New Phosphodiesterase-4 Inhibitor Ann. Pharmacother., June 1, 2006; 40(6): 1096 - 1104. [Abstract] [Full Text] [PDF]

				H. J. Kwak, J. S. Song, J. Y. Heo, S. D. Yang, J.-Y. Nam, and H. G. Cheon Roflumilast Inhibits Lipopolysaccharide-Induced Inflammatory Mediators via Suppression of Nuclear Factor-{kappa}B, p38 Mitogen-Activated Protein Kinase, and c-Jun NH2-Terminal Kinase Activation J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1188 - 1195. [Abstract] [Full Text] [PDF]

				S. Oger, C. Mehats, E. Dallot, D. Cabrol, and M.-J. Leroy Evidence for a Role of Phosphodiesterase 4 in Lipopolysaccharide-Stimulated Prostaglandin E2 Production and Matrix Metalloproteinase-9 Activity in Human Amniochorionic Membranes J. Immunol., June 15, 2005; 174(12): 8082 - 8089. [Abstract] [Full Text] [PDF]

				D. A. Wallace, L. A. Johnston, E. Huston, D. MacMaster, T. M. Houslay, Y.-F. Cheung, L. Campbell, J. E. Millen, R. A. Smith, I. Gall, et al. Identification and Characterization of PDE4A11, a Novel, Widely Expressed Long Isoform Encoded by the Human PDE4A cAMP Phosphodiesterase Gene Mol. Pharmacol., June 1, 2005; 67(6): 1920 - 1934. [Abstract] [Full Text] [PDF]

				D. Claveau, S. L. Chen, S. O'Keefe, D. M. Zaller, A. Styhler, S. Liu, Z. Huang, D. W. Nicholson, and J. A. Mancini Preferential Inhibition of T Helper 1, but Not T Helper 2, Cytokines in Vitro by L-826,141 [4-{2-(3,4-Bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a Potent and Selective Phosphodiesterase 4 Inhibitor J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 752 - 760. [Abstract] [Full Text] [PDF]

				S. Oger, C. Mehats, M. S. Barnette, F. Ferre, D. Cabrol, and M.-J. Leroy Anti-Inflammatory and Utero-Relaxant Effects in Human Myometrium of New Generation Phosphodiesterase 4 Inhibitors Biol Reprod, February 1, 2004; 70(2): 458 - 464. [Abstract] [Full Text] [PDF]

				H. A.M. Kerstjens and W. Timens Phosphodiesterase 4 Inhibitors: Antiinflammatory Therapy for Chronic Obstructive Pulmonary Disease at Last? Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 914 - 915. [Full Text] [PDF]

				R. K. Kumar, C. Herbert, P. S. Thomas, L. Wollin, R. Beume, M. Yang, D. C. Webb, and P. S. Foster Inhibition of Inflammation and Remodeling by Roflumilast and Dexamethasone in Murine Chronic Asthma J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 349 - 355. [Abstract] [Full Text] [PDF]

				P J Barnes Chronic obstructive pulmonary disease * 12: New treatments for COPD Thorax, September 1, 2003; 58(9): 803 - 808. [Full Text] [PDF]

				S. Oger, C. Mehats, E. Dallot, F. Ferre, and M.-J. Leroy Interleukin-1{beta} Induces Phosphodiesterase 4B2 Expression in Human Myometrial Cells through a Prostaglandin E2- and Cyclic Adenosine 3',5'-Monophosphate-Dependent Pathway J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5524 - 5531. [Abstract] [Full Text] [PDF]

				M. M. Billah, N. Cooper, M. Minnicozzi, J. Warneck, P. Wang, J. A. Hey, W. Kreutner, C. A. Rizzo, S. R. Smith, S. Young, et al. Pharmacology of N-(3,5-Dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline Carboxamide (SCH 351591), a Novel, Orally Active Phosphodiesterase 4 Inhibitor J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 127 - 137. [Abstract] [Full Text] [PDF]